The proposed acquisition would involve approximately $2.2 billion in upfront cash, with a further $1.2 billion potentially payable through milestone-based payments, according to the Financial Times. Discussions were ongoing at the time of reporting, and the transaction had not been confirmed by either company.

Ollin Biosciences is developing OLN324, an experimental treatment targeting wet age-related macular degeneration and diabetic macular oedema. Both conditions affect the retina and can lead to severe vision impairment.

Wet age-related macular degeneration is a major cause of vision loss among older adults, while diabetic macular oedema is associated with diabetes-related damage to blood vessels in the retina.

The proposed acquisition would provide Johnson & Johnson with an opportunity to expand its exposure to retinal medicines and strengthen its wider ophthalmology business. The company already has a presence in the eye-care market through its vision-care and contact-lens operations.

Ollin's drug candidate is expected to enter Phase 3 clinical trials. Its development has been supported by previous investment, including a $330 million fundraising earlier in 2026.

The potential transaction reflects the growing strategic importance of biotechnology acquisitions for established pharmaceutical companies seeking to strengthen research pipelines and secure access to innovative treatments.

For large pharmaceutical groups, acquiring promising drug developers can provide access to specialised research programmes without having to build every capability internally. However, clinical-stage acquisitions also carry considerable risks, particularly where the effectiveness and safety of experimental treatments remain subject to further testing.

The proposed deal comes amid substantial acquisition activity across the biotechnology industry. The Financial Times reported that 46 companies valued at more than $1 billion had been acquired during 2026, although dealmaking had slowed following a stronger first half of the year.

For Johnson & Johnson, the potential acquisition could strengthen its ophthalmology pipeline and provide another opportunity to expand its specialist medicines portfolio.

However, the ultimate commercial value of the transaction would depend on clinical results, regulatory approval, development costs and the treatment's ability to compete in the global ophthalmology market.

Neither Johnson & Johnson nor Ollin Biosciences commented on the reported discussions.